UNICA IRIS Institutional Research Information System

CARTA, MANOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 191.220
NA - Nord America 7.371
AS - Asia 2.986
SA - Sud America 413
Continente sconosciuto - Info sul continente non disponibili 334
AF - Africa 73
OC - Oceania 8
Totale 202.405
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 189.552
US - Stati Uniti d'America 7.260
SG - Singapore 1.208
CN - Cina 973
UA - Ucraina 374
SE - Svezia 342
BR - Brasile 325
DE - Germania 294
VN - Vietnam 266
FI - Finlandia 170
GB - Regno Unito 154
FR - Francia 145
HK - Hong Kong 106
KR - Corea 89
IN - India 83
CA - Canada 63
NL - Olanda 42
BD - Bangladesh 40
IQ - Iraq 36
AR - Argentina 35
JP - Giappone 31
RU - Federazione Russa 30
ES - Italia 29
MX - Messico 22
TR - Turchia 20
ID - Indonesia 17
PK - Pakistan 16
ZA - Sudafrica 16
BE - Belgio 15
SA - Arabia Saudita 15
VE - Venezuela 14
CO - Colombia 13
PH - Filippine 13
PL - Polonia 13
CZ - Repubblica Ceca 12
AT - Austria 11
EG - Egitto 11
MA - Marocco 11
AE - Emirati Arabi Uniti 9
KE - Kenya 9
PE - Perù 7
CH - Svizzera 6
JO - Giordania 6
PY - Paraguay 6
TH - Thailandia 6
TW - Taiwan 6
AZ - Azerbaigian 5
CL - Cile 5
JM - Giamaica 5
MY - Malesia 5
NZ - Nuova Zelanda 5
PS - Palestinian Territory 5
RO - Romania 5
TN - Tunisia 5
UZ - Uzbekistan 5
EC - Ecuador 4
IE - Irlanda 4
LB - Libano 4
LT - Lituania 4
NP - Nepal 4
AO - Angola 3
AU - Australia 3
BB - Barbados 3
BO - Bolivia 3
CR - Costa Rica 3
DZ - Algeria 3
PA - Panama 3
SN - Senegal 3
TT - Trinidad e Tobago 3
BG - Bulgaria 2
CI - Costa d'Avorio 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GR - Grecia 2
GT - Guatemala 2
HN - Honduras 2
HU - Ungheria 2
IR - Iran 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MN - Mongolia 2
NG - Nigeria 2
NI - Nicaragua 2
NO - Norvegia 2
OM - Oman 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
BH - Bahrain 1
BJ - Benin 1
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
ET - Etiopia 1
EU - Europa 1
GD - Grenada 1
GM - Gambi 1
KH - Cambogia 1
Totale 202.063
Salva come PNG Salva come JPEG
Città #
Cagliari 177.757
Uta 11.366
Fairfield 721
Ashburn 656
Singapore 621
Woodbridge 554
Chandler 420
Houston 382
San Jose 373
Ann Arbor 306
Boardman 262
Seattle 244
Wilmington 241
Cambridge 233
Dallas 229
Nyköping 206
Beijing 203
Jacksonville 200
Council Bluffs 158
Dearborn 121
Los Angeles 118
Santa Clara 112
Helsinki 98
Hong Kong 97
The Dalles 94
Ho Chi Minh City 90
Seoul 88
Hefei 87
New York 82
Shanghai 82
Nanjing 79
Lauterbourg 72
Hanoi 58
Boston 50
San Diego 45
Milan 44
Buffalo 39
Munich 38
Columbus 30
Guangzhou 28
Tokyo 26
Frankfurt am Main 24
Orem 24
Phoenix 24
Redwood City 24
Rome 24
São Paulo 23
Falls Church 20
Shenyang 20
Atlanta 19
London 19
Tianjin 19
Toronto 19
Washington 19
Dong Ket 18
Montreal 18
Norwalk 18
Redondo Beach 18
Chicago 17
Denver 16
Baghdad 15
Hebei 15
Nuremberg 15
San Francisco 15
Stockholm 15
Brooklyn 14
Chennai 14
Mountain View 14
Verona 14
Brussels 13
Changsha 13
Sassari 13
Amsterdam 12
Da Nang 12
Düsseldorf 12
Jiaxing 12
Orange 12
Mumbai 11
Padova 11
Pisa 11
Turku 11
Brno 10
Hangzhou 10
Dhaka 9
Haiphong 9
Nanchang 9
Pune 9
Zhengzhou 9
Manchester 8
Oristano 8
Porto Alegre 8
Riyadh 8
San Mateo 8
Hải Dương 7
Johannesburg 7
Nairobi 7
New Delhi 7
Newark 7
Paris 7
Rio de Janeiro 7
Totale 197.521
Salva come PNG Salva come JPEG
Nome #
Efficacy and safety of the 5-Hydroxytryptophan on Levodopa-Induced Motor Complications in Parkinson's disease 24.356
Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease 7.302
5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction 5.833
Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats 4.645
Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate 1-DOPA-induced dyskinesia 4.538
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease. 4.345
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease 4.301
The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease 4.089
Chronic tryptophan deprivation attenuates gating deficits induced by 5-HT 1A, but not 5-HT 2 receptor activation 3.742
Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson's disease? 3.736
Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia 3.697
Effect of selective and non-selective serotonin receptor activation on l-DOPA-induced therapeutic efficacy and dyskinesia in parkinsonian rats 3.588
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease 3.553
The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation 3.473
Essential fatty acids deficient diet modulates N-Acylethanolamide profile in rat's tissues 3.423
Tryptophan-deficient diet increases the neurochemical and behavioral response to amphetamine 3.378
Efficacy and safety of the 5-Hydroxytryptophan on Depression and Apathy in Parkinson's disease: a preliminary finding 3.348
Vitamin A deficiency produces spatial learning and memory impairment in rats 3.278
null 2.940
Biphasic effects of ethanol on acetylcholine release in the rat prefrontal cortex 2.882
Vitamin A deficiency induces motor impairments and striatal cholinergic dysfunction in rats 2.879
VGF peptides as novel biomarkers in Parkinson’s disease 2.824
Amphetamine usage, misuse, and addiction processes: an overview 2.651
Augmented cocaine-induced accumbal dopamine efflux, motor activity and place preference in rats fed with a tryptophan-deficient diet 2.638
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia 2.589
Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease 2.586
The serotonergic system in levodopa-induced dyskinesia 2.571
Optimization of continuous in vivo DOPA production and studies of ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats 2.381
Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: A preliminary finding 2.370
Startle Reflex as a possible biomarker associated with REM sleep behavior disorders in the prodromal stage of Parkinson's disease 2.350
Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration 2.302
null 2.298
Efficacy and Safety of the 5-Hydroxytryptophan on REM Sleep Behavior Disorder in Parkinson's Disease 2.272
Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease 2.271
Modulation of the Startle Response in REM Sleep Behavior Disorder 2.269
5-HT1 receptor agonists for the treatment of L-DOPA-induced dyskinesia: From animal models to clinical investigation 2.254
null 2.247
Foetal cell transplantation for Parkinson's disease: focus on graft-induced dyskinesia 2.200
Serotonin system implication in L-DOPA-induced dyskinesia: from animal models to clinical investigations 2.184
Role of serotonin neurons in L-DOPA- and graft-induced dyskinesia in a rat model of parkinson's disease 2.181
Efficacy and safety of the 5-Hydroxytryptophan on Depression and Apathy in Idiopathic Parkinson's disease 2.168
Amphetamine-induced rotation and L-DOPA-induced dyskinesia in the rat 6-OHDA model: A correlation study 2.166
The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson’s disease patients 2.025
On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats 1.937
Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia 1.794
L-DOPA and serotonergic neurons: functional implication and therapeutic perspectives in Parkinson's disease 1.773
null 1.663
null 1.607
null 1.604
Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and5-HT1B receptor agonists in the rat Parkinson model 1.554
null 1.471
Dyskinesia in Parkinson’s disease: a clinical complication and an open scientific question 1.432
BDNF Overexpression Increases Striatal D3Receptor Level at Striatal Neurons and Exacerbates D1-Receptor Agonist-Induced Dyskinesia 1.413
Role of serotonin neurons in the induction of L-DOPA- and graft-induced dyskinesias in Parkinson´s disease 1.405
Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease 1.273
Transcriptome analysis in a rat model of L-dopa-induced dyskinesia 1.259
Nurr1 is Required for Maintenance of Maturing and Adult Midbrain Dopamine Neurons 1.257
A simple method for large-scale generation of dopamine neurons from human embryonic stem cells 1.257
Serotonin/dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia: An update 1.225
Role of aberrant striatal dopamine D1 receptor/cAMP/protein kinase A/DARPP32 signaling in the paradoxical calming effect of amphetamine 1.120
A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease 1.117
Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease 1.100
The GTP-binding protein Rhes modulates dopamine signalling in striatal medium spiny neurons 1.095
Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms 1.093
Preliminary finding of a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of 5-hydroxytryptophan on REM sleep behavior disorder in Parkinson's disease 1.034
Vitamin A deficiency affects neither frontocortical acetylcholine nor working memory 982
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia 965
Involvement of the serotonin system in L-DOPA-induced dyskinesias 956
Effects of tryptophan deficiency on prepulse inhibition of the acoustic startle in rats 942
Critical involvement of cAMP/DARPP-32 and ERK signaling in L-DOPA-induced dyskinesia 915
5-Hydroxy-tryptophan for the treatment of l-DOPA-induced dyskinesia in the rat Parkinson's disease model 905
Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson’s disease 847
Altered dopaminergic innervation and amphetamine response in adult Otx2 conditional mutant miceAberrant accumbal innervation and sensitized motor response to amphetamine in Otx2 conditional mutant mice 837
null 780
Pharmacological validation of a mouse model of L-dopa-induced dyskinesia 757
Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression 749
Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson’s disease: effect of in vitro differentiation on graft survival and teratoma formation 723
BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats 707
Nusinersen Induces Disease-Severity-Specific Neurometabolic Effects in Spinal Muscular Atrophy 690
The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective 629
null 565
Perturbation of serine enantiomers homeostasis in the striatum of MPTP-lesioned monkeys and mice reflects the extent of dopaminergic midbrain degeneration 543
null 475
SMN deficiency perturbs monoamine neurotransmitter metabolism in spinal muscular atrophy 445
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats 429
Homeostasis of serine enantiomers is disrupted in the post-mortem caudate putamen and cerebrospinal fluid of living Parkinson's disease patients 381
Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia 337
null 320
Expanding the therapeutic potential of neuro(active)steroids: a promising strategy for hyperdopaminergic behavioral phenotypes 265
Effect of 5-alpha reductase inhibitors in animal models of Parkinson’s disease 212
Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease 199
The chronic use of serotonin norepinephrine reuptake inhibitors facilitates dyskinesia priming in early Parkinson's disease 124
Early Dopaminergic Dysfunction Induces PRO-VGF Changes in Blood and Brain of Rats with Alpha-Synuclein Overexpression 94
VGF INVOLVEMENT ON PARKINSON’S DISEASE 26
Totale 202.405
Salva come PNG Salva come JPEG
Categoria #
all - tutte 241.208
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 241.208
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20226.651 0 760 434 332 526 628 560 320 524 804 895 868
2022/202311.901 930 1.332 1.279 1.047 1.030 1.108 609 966 866 923 1.239 572
2023/202412.436 420 409 385 642 1.139 1.764 1.873 1.101 492 875 1.338 1.998
2024/202578.894 28.757 18.481 23.888 2.526 1.260 1.333 1.590 124 294 205 173 263
2025/20266.500 435 206 568 545 523 472 1.681 362 428 558 457 265
2026/2027769 177 592 0 0 0 0 0 0 0 0 0 0
Totale 202.405